Homepage Top Section2

Nearly $25m of the revenue is anticipated for the products under this contract. A human rabies immune globulin (HRIG), KAMRAB is designed for passive, transient post-exposure prophylaxis (PEP)

Designed to target oxidative stress related to RP, NPI-001 is the company’s investigational candidate. In preclinical studies, the therapy improved glutathione, which is said to be the most

The company has announced that soon, the injection will be available to ophthalmologists and their patients, and ongoing efforts are being made to ensure accessibility via public and

Developed by Fermion, FZ002-037 is an oral somatostatin receptor 4 (SSTR4) agonist. Under the terms of the agreement, Simcere will obtain exclusive rights for developing and commercialising the drug

This funding round was led by J2 Ventures and the Global Health Investment Corporation (GHIC). With this funding, the company’s total Series A equity value raised to over

The company is set to launch a multicentre Phase I trial in the US in the first quarter of this year. Axcynsis Therapeutics CEO Dr Zou Bin said:

BAFIERTAM will join TASCENSO ODT (fingolimod), Cycle’s other branded MS treatment. Both these therapies will be supported by Cycle’s hub programme, Cycle Vita. The company noted that, during

This designation is for Carteyva, an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy, as a second-line treatment for adults with this disease. It is developed independently

SPRIM Global Investments and William Taylor Nominees jointly led the funding round, which will support the conduct of a Phase I trial of RheumaGen’s lead candidate, RG0401. Anticipated